Most babies born with otoferlin deafness get cochlear implants in infancy and they are thus ineligible to the trial. The implants somewhat change the cochlea, which could hamper the interpretation of gene therapy outcomes. Blick ensures that every product they supply satisfies the highest requirements, from effectively-known names like https://artsuppliesonline.us/products/50-chipboard-sheets-11x17-brown-kraft-cardboard